Recent Advances in Myeloma: From Molecular Pathways to Drugs
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 September 2026
Special Issue Editor
Special Issue Information
Dear Colleagues,
In this Special Issue, we will highlight recent advances and developments in the field of myeloma pathobiology and therapeutics. The last decade has seen many notable successes in this field. These include the development of monoclonal antibodies, antibody–drug conjugates, bispecific T-cell engager antibodies, chimeric antigen T cells (CARTs), targeted small molecules, and combinations therapies. Still, much remains to be elucidated regarding the origins, classification, and risk stratification of myeloma, and opportunities for prevention, among other research areas. Many challenges need to be addressed, including determining the best front-line treatments, the role of stem cell transplantation, and the optimal sequencing of novel regimens, namely, where to position novel bispecific and CART cell therapies in the course of treatment and how to harness the available arsenal of the drugs in a manner that leads to cure. Effective treatment cannot be achieved without an understanding of the underlying origins and etiopathogenesis of the disease. This Special Issue will address many of these areas of active research to provide new insights.
Dr. Natalia Neparidze
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myeloma
- plasma cell disorders
- monoclonal gammopathy
- bispecifics
- T cell engagers
- CART therapy
- monoclonal antibodies
- MRD
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
